TimesSquare Capital Management’s BridgeBio Pharma BBIO Stock Holding History

TimesSquare Capital Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-411,595	Closed	-$19.3M	–	208
2021 Q3	$19.3M	Sell	411,595 -18,520	-4%	-$993K	0.17%	175
2021 Q2	$26.2M	Sell	430,115 -40,585	-9%	-$2.32M	0.21%	165
2021 Q1	$29M	Sell	470,700 -136,060	-22%	-$8.9M	0.25%	151
2020 Q4	$43.1M	Sell	606,760 -39,670	-6%	-$1.91M	0.35%	122
2020 Q3	$24.3M	Sell	646,430 -72,199	-10%	-$2.27M	0.23%	158
2020 Q2	$23.4M	Buy	718,629 +230,979	+47%	+$7.04M	0.22%	165
2020 Q1	$14.1M	Sell	487,650 -7,900	-2%	-$245K	0.17%	168
2019 Q4	$17.4M	Sell	495,550 -42,780	-8%	-$1.19M	0.15%	184
2019 Q3	$11.6M	Buy	538,330 +388,330	+259%	+$10.7M	0.1%	194
2019 Q2	$4.05M	Buy	+150,000	New	+$4.09M	0.03%	215

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

AIG

American International Group New York $609M AUM 23.67% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TimesSquare Capital Management's BBIO Position: Q4 2021 in Review

TimesSquare Capital Management sold out of BridgeBio Pharma (BBIO) in Q4 2021, closing a stake of 411,595 shares — an estimated $19.3M sold.

TimesSquare Capital Management first reported a position in BBIO in Q2 2019 and held it in 10 quarters. The position peaked at $43.1M in Q4 2020. 195 funds tracked by Wall St. Rank hold BBIO as of Q4 2021.

TimesSquare Capital Management reported no remaining BridgeBio Pharma position as of Q4 2021 after selling out during the quarter.
TimesSquare Capital Management sold 411,595 BridgeBio Pharma shares in Q4 2021, an estimated $19.3M.
TimesSquare Capital Management first reported a position in BridgeBio Pharma in Q2 2019 and held it in 10 quarters.
TimesSquare Capital Management's BridgeBio Pharma position peaked at $43.1M in Q4 2020.
195 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2021.

Based on TimesSquare Capital Management's 13F filing for Q4 2021, filed 4 Feb 2022.